Jes\u00fas Prada, the CEO and co-founder of Horus ML, describes his first encounter with artificial intelligence (AI) as “love at first sight.” Driven by the desire to make a positive impact on society, he found his calling in healthcare technology. With a balanced team of AI engineers and medical professionals, they launched AITheroscope<\/strong>\u2014an AI-based tool designed to detect atherosclerosis through retinal imaging.<\/p>\n Atherosclerosis, a silent condition that leads to heart attacks and strokes, poses a significant public health threat. Current risk assessment tools often overlook individuals with underlying conditions. Prada highlighted that nearly 50% of heart attacks occur in patients who show no prior symptoms. Alarmingly, studies reveal that up to 60% of individuals aged 35 to 55, classified as low-risk, may actually have undiagnosed atherosclerosis. <\/p>\n The retina serves as a unique window to the body’s vascular system. AITheroscope utilizes non-dilated retinal images to assess cardiovascular health. This method is faster and more accessible than traditional vascular ultrasounds, which can be expensive and limited in availability. <\/p>\n AITheroscope can provide real-time diagnostic reports in less than 10 seconds<\/strong>. By analyzing geometric parameters of the eye, such as tortuosity<\/strong> (complexity of the vascular network), overlap<\/strong> (abnormal crossings of blood vessels), and thickness<\/strong> of vascular walls, the tool generates quick assessments of a patient’s risk for atherosclerosis.<\/p>\n The technology underwent rigorous validation, utilizing over 1,000 retinal images compared with vascular ultrasounds, achieving a 95% sensitivity<\/strong> and 90% specificity<\/strong>. Currently in pilot testing across 18 healthcare centers and two hospitals<\/strong> in Madrid, AITheroscope complements physicians rather than replacing them. It streamlines the identification of patients who need further cardiology evaluations, especially in primary care settings.<\/p>\n The aim for Horus ML is to expand AITheroscope\u2019s commercial rollout throughout Spain and Europe, and they are already making plans for distribution in Mexico and Chile. Discussions are also underway to contribute to the REACT study<\/strong>, focusing on early atherosclerosis detection in younger populations. <\/p>\n Beyond AITheroscope, Horus ML is working on additional diagnostic tools, including an automated heart function assessment system integrated with AI for more reliable heart failure diagnostics. By making sophisticated analyses accessible in primary care, Horus ML is committed to enhancing preventive health strategies across healthcare systems. <\/p>\n In summary, AITheroscope signifies a groundbreaking advancement in early cardiovascular risk assessment, utilizing the power of AI to not only transform individual patient care but also contribute significantly to public health outcomes.<\/p>\nThe Challenge of Early Detection<\/h3>\n
Why the Retina Matters<\/h3>\n
Fast and Efficient Diagnosis<\/h3>\n
Validation and Pilot Implementation<\/h3>\n
Future Aspirations<\/h3>\n
Broader Impacts on Healthcare<\/h3>\n